

# Xiao-tian Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/128164/publications.pdf>

Version: 2024-02-01

92  
papers

3,166  
citations

279798

23  
h-index

189892

50  
g-index

101  
all docs

101  
docs citations

101  
times ranked

3313  
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of gastric cancer in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e535-e547.	10.7	418
2	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. <i>Cancer Communications</i> , 2019, 39, 1-31.	9.2	418
3	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <i>Cancer Communications</i> , 2021, 41, 747-795.	9.2	323
4	Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. <i>Nature Medicine</i> , 2022, 28, 1189-1198.	30.7	190
5	Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2021, 22, 1081-1092.	10.7	178
6	The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1251-1261.	3.4	155
7	Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. <i>Cell Death and Disease</i> , 2018, 9, 123.	6.3	76
8	Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. <i>Oncotarget</i> , 2014, 5, 6594-6602.	1.8	69
9	Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. <i>Clinical Cancer Research</i> , 2020, 26, 2337-2345.	7.0	66
10	Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. <i>Gastric Cancer</i> , 2019, 22, 1183-1192.	5.3	64
11	Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 748-756.	1.6	63
12	Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. <i>Gastric Cancer</i> , 2021, 24, 913-925.	5.3	61
13	PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. <i>Human Pathology</i> , 2016, 55, 182-189.	2.0	58
14	Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial. <i>Cancer Science</i> , 2016, 107, 486-490.	3.9	44
15	Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. , 2020, 8, e000374.		43
16	Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 5261-5271.	7.0	42
17	A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. <i>Cancer Letters</i> , 2011, 307, 47-52.	7.2	41
18	Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 129.	8.6	37

#	ARTICLE	IF	CITATIONS
19	Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study. <i>Cancer</i> , 2020, 126, 2086-2092.	4.1	37
20	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. <i>Cancer Biology and Medicine</i> , 2020, 17, 896-909.	3.0	35
21	A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. <i>Gastric Cancer</i> , 2018, 21, 782-791.	5.3	33
22	Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. <i>BMC Cancer</i> , 2019, 19, 705.	2.6	27
23	Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 646355.	2.8	27
24	Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. <i>BMC Medicine</i> , 2022, 20, 133.	5.5	27
25	Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. <i>Cancer Science</i> , 2006, 97, 938-944.	3.9	26
26	Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e233-e255.	2.3	26
27	Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. <i>JAMA Network Open</i> , 2019, 2, e197621.	5.9	25
28	Combination of microtubule associated protein-tau and $\beta$ -tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer. <i>European Journal of Cancer</i> , 2014, 50, 2328-2335.	2.8	24
29	Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. <i>European Journal of Surgical Oncology</i> , 2020, 46, e33-e39.	1.0	24
30	Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP. <i>World Journal of Gastroenterology</i> , 2018, 24, 266-273.	3.3	23
31	Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. <i>Clinical and Translational Medicine</i> , 2020, 10, e254.	4.0	23
32	HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 163-71.	2.2	23
33	Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. , 2020, 8, e000631.		22
34	Ultrasensitive Gastric Cancer Circulating Tumor Cellular <i>CLDN18.2</i> RNA Detection Based on a Molecular Beacon. <i>Analytical Chemistry</i> , 2021, 93, 665-670.	6.5	22
35	Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 579-588.	2.2	22
36	The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer. <i>Cancer Letters</i> , 2016, 380, 20-30.	7.2	20

#	ARTICLE	IF	CITATIONS
37	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. <i>Npj Precision Oncology</i> , 2021, 5, 36.	5.4	20
38	Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. <i>Frontiers in Oncology</i> , 2021, 11, 589022.	2.8	20
39	Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 287-302.	2.2	20
40	Impact of <sup>68</sup> Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 161-175.	6.4	19
41	Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis. <i>BioMed Research International</i> , 2018, 2018, 1-10.	1.9	18
42	Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12209.	12.2	18
43	Pyrotinib combined with CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients. <i>Clinical and Translational Medicine</i> , 2020, 10, e148.	4.0	17
44	Early change in peripheral CD4 <sup>+</sup> T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer. <i>Immunotherapy</i> , 2021, 13, 55-66.	2.0	15
45	Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients. <i>Cancer Letters</i> , 2021, 517, 78-87.	7.2	14
46	Nimotuzumab Plus Paclitaxel and Cisplatin as a 1 <sup>st</sup> -Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study. <i>Journal of Cancer</i> , 2019, 10, 1409-1416.	2.5	12
47	Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. <i>Genome Medicine</i> , 2021, 13, 175.	8.2	12
48	Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA. <i>Clinical Colorectal Cancer</i> , 2019, 18, 175-182.	2.3	11
49	PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 111-120.	4.2	11
50	Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm. <i>Cancer Medicine</i> , 2021, 10, 4855-4863.	2.8	10
51	Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System. <i>Medical Science Monitor</i> , 2020, 26, e924671.	1.1	10
52	Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 779-789.	2.5	10
53	miRNAs derived from plasma small extracellular vesicles predict organo-tropic metastasis of gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 360.	5.3	9
54	Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 31-39.	2.0	8

#	ARTICLE	IF	CITATIONS
55	Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing. <i>Oncology</i> , 2020, 98, 583-588.	1.9	7
56	Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study. <i>Radiation Oncology</i> , 2022, 17, 45.	2.7	7
57	Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-9.	1.5	6
58	The Inconsistent and Inadequate Reporting of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials. <i>Oncologist</i> , 2021, 26, e2239-e2246.	3.7	6
59	Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer. <i>JAMA Network Open</i> , 2022, 5, e224637.	5.9	6
60	Nimotuzumab plus paclitaxel and cisplatin as 1st line treatment for unresectable esophageal squamous cell carcinoma: Long term follow-up of survival in a phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15573-e15573.	1.6	5
61	GIs-010, a novel anti-PD-1 mAb in Chinese advanced gastrointestinal tumor: Result of a phase Ib clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 125-125.	1.6	5
62	Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 761110.	2.8	5
63	Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites. <i>Journal of International Medical Research</i> , 2021, 49, 030006052098666.	1.0	4
64	A multicenter study assessing the prevalence of germline genetic alterations in Chinese gastric-cancer patients. <i>Gastroenterology Report</i> , 2021, 9, 339-349.	1.3	4
65	Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. <i>Cancer Biology and Medicine</i> , 2022, 19, 1139-1149.	3.0	4
66	Clinicopathological Characteristics and Response to Chemotherapy in Treatment-Naive Epstein-Barr Virus Associated Gastric Cancer: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 611676.	2.8	3
67	Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma. <i>Neuroendocrinology</i> , 2022, 112, 733-743.	2.5	3
68	Response to the rechallenge of combination immunotherapy in a patient with late-stage gastric cancer: case report. <i>Annals of Palliative Medicine</i> , 2021, .	1.2	2
69	Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: A single center prospective clinical trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4097-4097.	1.6	2
70	A randomized, multicenter, controlled study to compare perioperative chemotherapy of oxaliplatin combined with TS-1 (SOX) versus SOX or oxaliplatin with capecitabine (XELOX) as post-operative chemotherapy in locally advanced gastric adenocarcinoma with D2 dissection (RESOLVE Trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4136-TPS4136.	1.6	2
71	Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment. <i>BMC Cancer</i> , 2022, 22, 355.	2.6	2
72	Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 835389.	2.8	2

#	ARTICLE	IF	CITATIONS
73	Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4017-4017.	1.6	2
74	Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2008, 7, 400-403.	0.1	1
75	The ctDNA in peritoneal effusion of advanced gastric cancer for auxiliary diagnosis of peritoneal metastasis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15516-e15516.	1.6	1
76	Association of HLA class I genotype with outcomes of gastrointestinal cancer patients with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16551-e16551.	1.6	1
77	Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 3356.	3.3	1
78	Efficacy of paclitaxel plus cisplatin in advanced esophageal squamous cell cancer: Further analysis of single center, prospective study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15174-e15174.	1.6	1
79	FAT4 mutation as a potential predictive biomarker for immunotherapy combined with anti-angiogenic therapy in MSS metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15504-e15504.	1.6	1
80	Germline HLA-B evolutionary divergence to influence efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16101-e16101.	1.6	0
81	Reply to M. A. Liu et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 2519-2519.	1.6	0
82	A phase II study of sequential Irinotecan plus cisplatin (IP) and octreotide LAR as first-line treatment of metastatic or inoperable poorly differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15156-e15156.	1.6	0
83	Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: Final results of a single-center prospective clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4070-4070.	1.6	0
84	Clinical characters and prognostic factors of young female patients (pts) with metastatic gastric adenocarcinoma (GC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 133-133.	1.6	0
85	Development of a prognostic index for gastric cancer with liver metastasis at the initial diagnosis: A single center retrospective study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16001-e16001.	1.6	0
86	A multi-institutional investigation assessing prevalence of germline genetic alterations in Chinese patients with gastric carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13020-e13020.	1.6	0
87	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint inhibitor for advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 306-306.	1.6	0
88	Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16014-e16014.	1.6	0
89	Prognostic and predictive impact of circulating tumor DNA in advanced gastric cancer treated with immune checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16019-e16019.	1.6	0
90	Genomic characterization of Chinese locally advanced or metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16085-e16085.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Abstract 5129: Clinical implication of plasma ctDNA features in HER2-positive gastric cancer treated with combinations of trastuzumab & anti-PD-1 agents. <i>Cancer Research</i> , 2022, 82, 5129-5129.	0.9	0
92	ChosenHRDw: A novel tool for the detection of homologous recombination deficiency(HRD) using low-pass whole-genome sequencing.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17573-e17573.	1.6	0